An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin Alfa in Paediatric Subjects From Birth to Less Than 1 Year of Age With Anemia Due to Chronic Kidney Disease
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2016
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 07 Jun 2017 Biomarkers information updated
- 16 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment due to Difficulty in recruitment.
- 27 Apr 2016 Planned initiation date changed from 1 Apr 2016 to 1 May 2016.